Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RelabotulinumtoxinA for Glabellar Frown Lines
NCT02236312Phase 2Completed
- Sponsor
- Galderma
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of relabotulinumtoxinA in glabellar rhytides, sponsored by Galderma. Started Sep 2014; status: completed.
02
Drugs
relabotulinumtoxinA
03
Conditions
glabellar rhytides
Beyond the preview
Go deeper on NCT02236312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02236312.